[go: up one dir, main page]

WO2009014217A1 - 二環性ピロール誘導体 - Google Patents

二環性ピロール誘導体 Download PDF

Info

Publication number
WO2009014217A1
WO2009014217A1 PCT/JP2008/063429 JP2008063429W WO2009014217A1 WO 2009014217 A1 WO2009014217 A1 WO 2009014217A1 JP 2008063429 W JP2008063429 W JP 2008063429W WO 2009014217 A1 WO2009014217 A1 WO 2009014217A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
optionally substituted
hydrogen atom
alkyl group
pyrrole derivative
Prior art date
Application number
PCT/JP2008/063429
Other languages
English (en)
French (fr)
Inventor
Hitoshi Hochigai
Hiroyuki Nakahira
Junya Ikeda
Masahiro Takamura
Satoshi Suetsugu
Yohei Ikuma
Atsushi Suwa
Original Assignee
Dainippon Sumitomo Pharma Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Sumitomo Pharma Co., Ltd. filed Critical Dainippon Sumitomo Pharma Co., Ltd.
Publication of WO2009014217A1 publication Critical patent/WO2009014217A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

　本発明は、レニン阻害剤として有用な、下記式（Ｉ）の化合物、またはその薬学上許容される塩を提供する。 　式（Ｉ）中、Ｇは、下記（ａ’）等で表される基であり；Ｒ１ａは、置換されてもよいＣ１－１０アルキル基等であり；Ｒ１ｂ、Ｒ１ｃ、Ｒ１ｄおよびＲ１ｅは、各々独立して、同一または異なって、水素原子等であり；Ｒ１ｆは、水素原子、ハロゲン原子等であり；Ｒ２は、置換されてもよいＣ１－６アルキル基等であり；Ｒ３ａ、Ｒ３ｂ、Ｒ３ｃおよびＲ３ｄは、各々独立して、同一または異なって、基：－Ａ－Ｂ（ここにおいて、Ａは、単結合等であり、Ｂは、水素原子、置換されてもよいＣ１－６アルキル基等である。）等であり；ｎは１等である。
PCT/JP2008/063429 2007-07-26 2008-07-25 二環性ピロール誘導体 WO2009014217A1 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007195262 2007-07-26
JP2007-195262 2007-07-26
JP2007-341367 2007-12-28
JP2007341367A JP2010229034A (ja) 2007-07-26 2007-12-28 二環性ピロール誘導体

Publications (1)

Publication Number Publication Date
WO2009014217A1 true WO2009014217A1 (ja) 2009-01-29

Family

ID=40281463

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/063429 WO2009014217A1 (ja) 2007-07-26 2008-07-25 二環性ピロール誘導体

Country Status (2)

Country Link
JP (1) JP2010229034A (ja)
WO (1) WO2009014217A1 (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009154300A3 (en) * 2008-06-19 2010-06-03 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2010150840A1 (ja) 2009-06-24 2010-12-29 大日本住友製薬株式会社 Ｎ－置換－環状アミノ誘導体
US8389511B2 (en) 2007-12-19 2013-03-05 Dainippon Sumitomo Pharma Co., Ltd. Bicyclic heterocyclic derivative
US9018374B2 (en) 2010-06-16 2015-04-28 Takeda Pharmaceutical Company Limited Crystal of amide compound

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106349306A (zh) * 2016-08-23 2017-01-25 广东优尼德生物科技有限公司 一种5‑溴‑4‑氯‑3‑吲哚基‑α‑D‑N‑乙酰基神经氨酸钠盐的合成工艺

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07503711A (ja) * 1992-01-10 1995-04-20 藤沢薬品工業株式会社 タキキニン拮抗作用を有するペプチド類
WO2006020598A2 (en) * 2004-08-10 2006-02-23 Incyte Corporation Amido compounds and their use as pharmaceuticals

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07503711A (ja) * 1992-01-10 1995-04-20 藤沢薬品工業株式会社 タキキニン拮抗作用を有するペプチド類
WO2006020598A2 (en) * 2004-08-10 2006-02-23 Incyte Corporation Amido compounds and their use as pharmaceuticals

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8389511B2 (en) 2007-12-19 2013-03-05 Dainippon Sumitomo Pharma Co., Ltd. Bicyclic heterocyclic derivative
WO2009154300A3 (en) * 2008-06-19 2010-06-03 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US8466282B2 (en) 2008-06-19 2013-06-18 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US8664380B2 (en) 2008-06-19 2014-03-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
AU2009261153B2 (en) * 2008-06-19 2014-05-22 Scohia Pharma, Inc. Heterocyclic compound and use thereof
EA019755B1 (ru) * 2008-06-19 2014-06-30 Такеда Фармасьютикал Компани Лимитед Гетероциклическое соединение и его применение
US9045436B2 (en) 2008-06-19 2015-06-02 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US9221836B2 (en) 2008-06-19 2015-12-29 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2010150840A1 (ja) 2009-06-24 2010-12-29 大日本住友製薬株式会社 Ｎ－置換－環状アミノ誘導体
US8658639B2 (en) 2009-06-24 2014-02-25 Dainippon Sumitomo Pharma Co., Ltd N-substituted-cyclic amino derivative
US9018374B2 (en) 2010-06-16 2015-04-28 Takeda Pharmaceutical Company Limited Crystal of amide compound

Also Published As

Publication number Publication date
JP2010229034A (ja) 2010-10-14

Similar Documents

Publication Publication Date Title
WO2008136457A1 (ja) 含窒素芳香族誘導体
WO2009078481A1 (ja) 二環性へテロ環誘導体
EG25765A (en) Pyrido [2,3-B] pyrazine derivatives useful as herbicidal compounds
WO2006049835A3 (en) Indole and benzimidazole derivatives
WO2009048101A1 (ja) アミド化合物
WO2008120725A1 (ja) 新規ピロリノン誘導体およびそれを含有する医薬組成物
WO2009098448A8 (en) Compounds
IL189276A0 (en) Novel crystalline form of a pyridazino [4,5-b] indole derivative
WO2007076245A3 (en) Novel hydrogen sulfate salt
WO2008096829A1 (ja) ３環系化合物
WO2009042114A3 (en) Phenazine derivatives and uses thereof
RS54101B1 (en) A CYCLOPROPAN UNIT
WO2010066629A3 (en) Novel azaindoles
WO2009014217A1 (ja) 二環性ピロール誘導体
WO2007057225A3 (en) Process for making montelukast and intermediates therefor
WO2009020137A1 (ja) アミノピラゾールアミド誘導体
WO2009005002A1 (ja) キノロン誘導体
ZA200904440B (en) 6-Benzyl-2,3,4,7-Tetrahydro-indolo [2,3-C] quinoline compounds useful as PDE5 inhibitors
WO2007039125A3 (en) An optically active thyroid receptor agonist and optically active key intermediates in its production
WO2008093737A1 (ja) アミド誘導体
IL193155A0 (en) Tetrahydronaphthaline derivatives, methods for the production and use thereof as anti-inflammatory agents
WO2006039250A3 (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
WO2006066950A3 (de) Tricyclische aminoalkohole, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer
WO2009072649A1 (ja) ４－アリールフェニル誘導体
WO2009085176A3 (en) Use of tetramic acid derivatives for controlling nematodes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08791673

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08791673

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP